Format

Send to

Choose Destination
Annu Rev Pharmacol Toxicol. 2012;52:481-503. doi: 10.1146/annurev-pharmtox-010611-134623. Epub 2011 Oct 24.

Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective.

Author information

1
Centre for Pharmaceutical Nanotechnology and Nanotoxicology, University of Copenhagen, DK-2100 Copenhagen Ø, Denmark. momo@farma.ku.dk

Abstract

Intravenously injected nanoparticulate drug carriers provide a wide range of unique opportunities for site-specific targeting of therapeutic agents to many areas within the vasculature and beyond. Pharmacokinetics and biodistribution of these carriers are controlled by a complex array of interrelated core and interfacial physicochemical and biological factors. Pertinent to realizing therapeutic goals, definitive maps that establish the interdependency of nanoparticle size, shape, and surface characteristics in relation to interfacial forces, biodistribution, controlled drug release, excretion, and adverse effects must be outlined. These concepts are critically evaluated and an integrated perspective is provided on the basis of the recent application of nanoscience approaches to nanocarrier design and engineering. The future of this exciting field is bright; some regulatory-approved products are already on the market and many are in late-phase clinical trials. With concomitant advances in extensive computational knowledge of the genomics and epigenomics of interindividual variations in drug responses, the boundaries toward development of personalized nanomedicines can be pushed further.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center